Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis

Authors

  • Barbara Kind Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany https://orcid.org/0009-0002-5254-6411
  • Christina Pham Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany https://orcid.org/0009-0000-3144-5959
  • Luise Heinrich Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany https://orcid.org/0009-0002-2878-2019
  • Tatjana Honstein Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany https://orcid.org/0009-0001-2897-964X
  • Annice Heratizadeh Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany https://orcid.org/0000-0002-9231-9865
  • Inken Harder Department of Dermatology and Allergy, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany https://orcid.org/0000-0002-3079-0440
  • Dora Stölzl Department of Dermatology and Allergy, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany https://orcid.org/0000-0001-7321-7305
  • Petra Staubach-Renz Clinic for Dermatology, University Hospital, Mainz, Germany https://orcid.org/0000-0002-2276-0284
  • Thomas Schaefer Practice Dr. med. Thomas Schaefer and Dr. med. Doreen Belz, Derma Koeln, Cologne, Germany
  • Susanne Abraham Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany; Department of Dermatology, University Allergy Center, Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany https://orcid.org/0000-0001-7457-6481
  • Matthias Augustin Institute for Health Services Research in Dermatology Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany https://orcid.org/0000-0002-4026-8728
  • Jutta Ramaker-Brunke Practice 'Die Hautärzte' Braunschweig, Braunschweig, Germany
  • Andreas Pinter Department of Dermatology, Venereology and Allergology, Clinical Research, University Hospital, Frankfurt am Main, Germany https://orcid.org/0000-0002-1330-1502
  • Kathrin Meinhardt Practice Kathrin Meinhardt, Beckum, Germany
  • Sven Quist Dermatology Clinic, Helix Medical Ecellence Center Mainz, Mainz, Germany https://orcid.org/0000-0002-9548-7813
  • Sabine Anders Practice Dr. med. Sabine Anders, Munich, Germany
  • Beate Schwarz Practice Dr. med. Beate Schwarz, Langenau, Germany
  • Michael Schulz-Kiesow Practice Dr. med. Michael Schulz-Kiesow and Dr. med. Inken Reimers, Lübeck, German
  • Sabine Steinke Hohenzollernring Dermatology Practice, Münster, Germany
  • Nicole Adler Hautärzte am Fastnachtsbrunnen, FÄ Nicole Adler, Mainz, Germany
  • Christiane Handrick Practice Dr. med. Christiane Handrick, Berlin, Germany
  • Knut Schaekel Department of Dermatology, University Hospital, Heidelberg, Germany https://orcid.org/0000-0001-6344-7799
  • Michael Sticherling Department of Dermatology, University, German Center for Immunotherapy, Erlangen, Germany
  • Anne Bong Practice Dr. med. Anne Bong, Emmerich, Germany
  • Felix D. Jacobs Practice DERMAKULM, Kulmbach, Germany
  • Bernd Großmann Practice Dr. med. Bernd Großmann, Koblenz, Germany
  • Maren Stahl Stahl, M., Practice Dr. med. Maren Stahl, Osterode, Germany
  • Carl-Philipp Buerkle Skin and laser medicine Kinzigtal, Practice Dr. med. Bürkle, Haslach, Germany
  • Hannah L. Gorriahn-Maiterth Practice Dermasana, Karlsruhe, Germany
  • Tilo Biedermann Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany https://orcid.org/0000-0002-5352-5105
  • Jochen Schmitt Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus and Carl Gustav Carus Faculty of Medicine, Technische Universitaet Dresden, Dresden, Germany https://orcid.org/0000-0003-0264-0960
  • Stephan Weidinger Department of Dermatology and Allergy, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany https://orcid.org/0000-0003-3944-252X
  • Thomas Werfel Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany https://orcid.org/0000-0001-6830-7672

DOI:

https://doi.org/10.2340/actadv.v106.adv-2026-0542

Keywords:

atopic dermatitis, lebrikizumab, daily practice, HOME Core Outcome Set, TREATgermany, biologics, quality of life

Abstract

Atopic dermatitis (AD) is driven by type 2 inflammation, with interleukin-13 (IL-13) as one of the central operators. Lebrikizumab is a monoclonal antibody that inhibits IL-13 signalling. Adult patients with moderate-to-severe AD who received lebrikizumab in the TREATgermany registry until 12/2024 were selected, and patient characteristics as well as effectiveness and safety outcomes after 1, 3 and 6 months were evaluated. A total of 108 patients were initiated on lebrikizumab, with 80 having follow-up data available for this analysis (“registry cohort”). Forty-one patients were switched to lebrikizumab without a “washout period” from another advanced systemic therapy (“switchers”). The mean Eczema Area and Severity Index (EASI) decreased from 14.8 at baseline to 5.6 and 3.0 at month 3 and month 6 and was comparable between switchers and nonswitchers. Clinically meaningful improvements were also seen across all patient reported outcomes (PROs) equally in both groups, e.g. a decrease of the mean peak pruritus numeric rating scale (PP-NRS) from 6.6 to 3.8 and 3.4 and the Dermatology Life Quality Index (DLQI) from 11.9 to 4.9 and 4.8. Overall, adverse events (AEs) were reported for 26.6% of patients within the first 3. The most frequently reported AE was conjunctivitis or other ocular complications, reported in 13 patients (20.3%). 32 patients (40%) had an initial EASI≥16 and were comparable to patients in lebrikizumab phase 3 studies. In this “trial-like” cohort, EASI-75 and EASI-90 response rates were 60% and 26.7% at month 3 and 70% and 50% at month 6. Lebrikizumab shows effectiveness in routine care well comparable to observations made in randomized controlled trials.

Downloads

Download data is not yet available.

References

Armario-Hita JC, Carrascosa JM, Flórez Á, Herranz P, Pereyra-Rodríguez JJ, Serra-Baldrich E, et al. Pruritus and pain constitute the main negative impact of atopic dermatitis® from the patient’s perspective: A systematic review. Dermatitis 2024; 35: 216–234. DOI: https://doi.org/10.1089/derm.2023.0163

Birkner T, Siegels D, Heinrich L, Haufe E, Abraham S, Heratizadeh A, et al. Itch, sleep loss, depressive symptoms, fatigue, and productivity loss in patients with moderate-to-severe atopic dermatitis: Analyses of TREATgermany registry data. J Dtsch Dermatol Ges 2023; 21: 1157–1168. DOI: https://doi.org/10.1111/ddg.15159

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers 2018; 4: 1. DOI: https://doi.org/10.1038/s41572-018-0001-z

Lee W, Chaudhary F, Agrawal DK. Environmental influences on atopic eczema. J Environ Sci Public Health 2024; 8: 101–115. DOI: https://doi.org/10.26502/jesph.96120209

Traidl S, Werfel T, Traidl-Hoffmann C. Atopic eczema: Pathophysiological findings as the beginning of a new era of therapeutic options. Handb Exp Pharmacol 2022; 268: 101–115. DOI: https://doi.org/10.1007/164_2021_492

Le Floc’h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy 2020; 75: 1188–1204. DOI: https://doi.org/10.1111/all.14151

Wollenberg A, Schnopp C. Evolution of conventional therapy in atopic dermatitis. Immunol Allergy Clin North Am 2010; 30: 351–368. DOI: https://doi.org/10.1016/j.iac.2010.06.005

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287–2303. DOI: https://doi.org/10.1016/S0140-6736(17)31191-1

Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol 2020; 156: 1333–1343. DOI: https://doi.org/10.1001/jamadermatol.2020.3260

Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021; 184: 450–463. DOI: https://doi.org/10.1111/bjd.19573

Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol 2021; 157: 1047–1055. DOI: https://doi.org/10.1001/jamadermatol.2021.3023

Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396: 255–266. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7

Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A, et al. S3 guideline atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groups. J Dtsch Dermatol Ges 2024; 22: 137–153. DOI: https://doi.org/10.1111/ddg.15230

Werfel T, Heratizadeh A, Aberer W, Augustin M, Biedermann T, Bauer A, et al. S3 guideline atopic dermatitis: Part 2 - Systemic treatment. J Dtsch Dermatol Ges 2024; 22: 307–320. DOI: https://doi.org/10.1111/ddg.15229

Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): Results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet 2024; 404: 445–460. DOI: https://doi.org/10.1016/S0140-6736(24)01203-0

Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select 2021; 5: 274–286. DOI: https://doi.org/10.5414/ALX02262E

Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, et al. Systemic immunomodulatory treatments for atopic dermatitis: Living systematic review and network meta-analysis update. JAMA Dermatol 2024; 160: 936–944. DOI: https://doi.org/10.1001/jamadermatol.2024.2192

Silverberg JI, Bieber T, Paller AS, Beck L, Kamata M, Puig L, et al. Lebrikizumab vs other systemic monotherapies for moderate-to-severe atopic dermatitis: Network meta-analysis of efficacy. Dermatol Ther (Heidelb) 2025; 15: 615–633. DOI: https://doi.org/10.1007/s13555-025-01357-7

Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 2023; 388: 1080–1091. DOI: https://doi.org/10.1056/NEJMoa2206714

Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: A randomized clinical trial (ADhere). JAMA Dermatol 2023; 159: 182–191. DOI: https://doi.org/10.1001/jamadermatol.2022.5534

de Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C, et al. Biologics to treat atopic dermatitis: Effectiveness, safety, and future directions. Allergy 2026; 81: 326–344. DOI: https://doi.org/10.1111/all.70061

Bosma AL, Musters AH, Bloem M, Gerbens LAA, Middelkamp-Hup MA, Haufe E, et al. Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce. J Eur Acad Dermatol Venereol 2023; 37: 123–136. DOI: https://doi.org/10.1111/jdv.18566

Heratizadeh A. CORRIGENDUM: Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD registry TREATgermany. Acad Dermatol Venereol 2023; 37: 633–634. DOI: https://doi.org/10.1111/jdv.18838

Heratizadeh A, Haufe E, Stölzl D, Abraham S, Heinrich L, Kleinheinz A, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol 2020; 34: 1263–1272. DOI: https://doi.org/10.1111/jdv.16078

Kind B, Heinrich L, Werfel T, Schmitt J, Weidinger S. Treatment of moderate-to-severe atopic dermatitis with upadacitinib: Results from an interim analysis of the TREATgermany registry. Acta Derm Venereol 2025; 105: adv42206. DOI: https://doi.org/10.2340/actadv.v105.42206

Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol 2017; 177: 1316–1321. DOI: https://doi.org/10.1111/bjd.15641

Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: An interpretability study. Br J Dermatol 2015; 172: 1353–1357. DOI: https://doi.org/10.1111/bjd.13662

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The Eczema Area and Severity Index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11–18. DOI: https://doi.org/10.1034/j.1600-0625.2001.100102.x

Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, Taïeb A. Clinical validation and guidelines for the SCORAD index: Consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10–19. DOI: https://doi.org/10.1159/000245677

Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326–1332. DOI: https://doi.org/10.1111/bjd.12590

Howells LM, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: RECAP of atopic eczema (RECAP). Br J Dermatol 2020; 183: 524–536. DOI: https://doi.org/10.1111/bjd.18780

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--A simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216. DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x

Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121–1123. DOI: https://doi.org/10.1001/archneur.1989.00520460115022

Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging 1997; 12: 277–287. DOI: https://doi.org/10.1037/0882-7974.12.2.277

R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.

Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi SI, et al. 24-week real-world effectiveness and safety of lebrikizumab for atopic dermatitis in Japan: An analysis stratified by prior systemic therapy. Dermatitis 2025: derm20250045. DOI: https://doi.org/10.1089/derm.2025.0045

Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 2023; 188: 740–748. DOI: https://doi.org/10.1093/bjd/ljad022

Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, et al. Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: A 52-week, open-label, phase 3 study. Dermatol Ther (Heidelb) 2023; 13: 1517–1534. DOI: https://doi.org/10.1007/s13555-023-00942-y

Downloads

Additional Files

Published

2026-08-13

How to Cite

Kind, B., Pham, C., Heinrich, L., Honstein, T., Heratizadeh, A., Harder, I., … Werfel, T. (2026). Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis. Acta Dermato-Venereologica, 106, adv–2026. https://doi.org/10.2340/actadv.v106.adv-2026-0542

Issue

Vol. 106 (2026)

Section

Articles

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC